[Research and development strategy of antithrombotic agents: pharmacology of the oral factor Xa-inhibitor edoxaban]

Nihon Yakurigaku Zasshi. 2010 Aug;136(2):83-7. doi: 10.1254/fpj.136.83.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Atrial Fibrillation / complications
  • Clinical Trials, Phase III as Topic
  • Drug Design*
  • Factor Xa Inhibitors*
  • Fibrinolytic Agents* / administration & dosage
  • Fibrinolytic Agents* / classification
  • Fibrinolytic Agents* / pharmacology
  • Humans
  • Intracranial Thrombosis / etiology
  • Intracranial Thrombosis / prevention & control
  • Postoperative Complications / prevention & control
  • Pyridines* / administration & dosage
  • Pyridines* / pharmacology
  • Secondary Prevention
  • Thiazoles* / administration & dosage
  • Thiazoles* / pharmacology
  • Thrombosis / drug therapy*
  • Venous Thrombosis / prevention & control

Substances

  • Factor Xa Inhibitors
  • Fibrinolytic Agents
  • Pyridines
  • Thiazoles
  • edoxaban